Biofrontera (BFRI) Projected to Post Quarterly Earnings on Thursday

Biofrontera (NASDAQ:BFRI) will likely be announcing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.1150) per share and revenue of $10.25 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 11:00 AM ET.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Thursday, March 19th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.21. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $16.15 million. On average, analysts expect Biofrontera to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Trading Down 9.0%

Shares of BFRI stock opened at $1.01 on Wednesday. Biofrontera has a twelve month low of $0.54 and a twelve month high of $1.19. The firm has a 50-day moving average price of $0.97 and a 200 day moving average price of $0.90. The company has a current ratio of 1.52, a quick ratio of 1.40 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $12.13 million, a price-to-earnings ratio of -0.98 and a beta of 0.89.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC grew its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. 10.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.75.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.